纳斯达克： -- -- --

最近浏览

实时行情

意见反馈

诺华

NYSE:NVS 延时15分钟
  • 今开：--
    昨收：--
  • 今日区间：--
    52周区间：--
  • 成交量：--
    成交额：--
  • 市 值：--
    市盈率：--
  • 振幅：
    每股收益：
成交量

董事会

Hans J rg Reinhardt
Hans J rg Reinhardt currently works at Novartis, Inc., as Chairman from 2013, Novartis International AG, as Chairman-Supervisory Board, Novartis AG, as Chairman from 2013, Novartis Pharmaceuticals Corp., as Chairman, Novartis Institutes for Biomedical Research, Inc., as Chairman, Novartis Pharma AG, as Chairman from 2013, Novartis Pharma BV, as Chairman, Swiss Re AG, as Vice Chairman, Novartis Foundation, as Chairman from 2013, Institut f r molekulare und klinische Ophthalmologie Basel, as Chairman-Trustees Board, Abadia Retuerta SA, as Chairman, Novartis Finance Corp, as Chairman, International Federation of Pharmaceutical Manufacturers, as Council Member from 2010, and Helmholtz-Gemeinschaft Deutscher Forschungszentren eV, as Member. Dr. Reinhardt also formerly worked at Bayer HealthCare AG, as Chairman-Management Board in 2013, Novartis Institute for Functional Genomics, Inc., as Chairman from 2000 to 2010, Lonza Group AG, as Director from 2012 to 2013, Novartis Institute for Functional Genomics, Inc., as Director, Novartis AG, as Chief Operating Officer from 2008 to 2010, MorphoSys AG, as Member-Supervisory Board from 2001 to 2004, and Sandoz Pharmaceuticals AG, as Head-Development. Dr. Reinhardt received his doctorate degree from Universit t des Saarlandes.
Charles L. Sawyers
Charles L. Sawyers is the founder of Aragon Pharmaceuticals, Inc. (2009) and Oric Pharmaceuticals, Inc. (2014). Current jobs include Chairman-Human Oncology & Pathogenesis Program at Memorial Sloan Kettering Cancer Center (2006), Independent Non-Executive Director at Novartis AG (2013), Senior Advisor at Arsenal Capital Management LP, Member at National Academy of Sciences, Member at American Academy of Arts & Sciences, Member at National Academy of Medicine (United States), Trustee at Cold Spring Harbor Laboratory, Inc., Science Partner at The Column Group LLC, and Professor at Weill Cornell Graduate School of Medical Sciences (2008). Former jobs include Chief Associate at the University of California, Los Angeles (1996-2006), President at American Association for Cancer Research (2013-2014), and President at American Society for Clinical Investigation. Education includes undergraduate degree from Princeton University and doctorate from The Johns Hopkins University School of Medicine.
William Thomas Winters
William Thomas Winters was the founder of Renshaw Bay LLP, founded in 2011, where the title held was Chief Executive Officer. Current jobs include Group Chief Executive Officer & Executive Director at Standard Chartered Plc since 2015, Chief Executive Officer at Standard Chartered Bank Ltd. since 2019, Chairman at Coronet Theatre LLC, Director at Colgate University, Director at Standard Chartered Holdings Ltd. since 2015, Director at Young Vic Theatre Co., Director at Print Room At The Coronet, Member-Market Monitoring Group at The Institute of International Finance, Inc., Member-Overseers Board at International Rescue Committee, Inc., Group Chief Executive at Standard Chartered Bank (Broker) since 2015, Member at The World Bank Group, and Member at Glasgow Financial Alliance for Net Zero. Former jobs include Co-Chief Executive Officer-Investment Bank at JPMorgan Chase & Co. from 2004 to 2009, Chief Executive Officer-Investment Bank at JPMorgan Chase & Co., Inc. from 2004 to 2010, Independent Non-Executive Director at Novartis International AG from 2015 to 2025, Non-Executive Director at RIT Capital Partners Plc, Non-Executive Director at Pension Insurance Corp. Plc in 2015, Director at Climate Impact X Pte Ltd., Independent Non-Executive Director at Novartis AG from 2013 to 2025, Commissioner at Independent Commission on Banking from 2010 to 2011, and Trustee at International Rescue Committee UK. Education includes undergraduate degree from Colgate University and MBA from The Wharton School of the University of Pennsylvania.
Nancy C. Andrews
Nancy C. Andrews currently serves as Independent Director and Director at Charles River Laboratories International, Inc. and Charles River Laboratories, Inc. since 2020. She is an Independent Non-Executive Director at Novartis AG since 2015 and a Director at Novartis International AG. She holds the position of Independent Director at Maze Therapeutics, Inc. since 2021. She is Chief Scientific Officer & Executive VP at The Children's Hospital Corp. since 2021. She is a Member of the National Academy of Medicine (United States) since 2019, a Member of the Scientific Management Review Board, a Member of MIT Corp. (United States), a Professor at Harvard Medical School since 2023, and Secretary-Home of the National Academy of Sciences since 2023. Former roles include Chairman of The Burroughs Wellcome Fund from 2011 to 2019 and Chairman of the American Academy of Arts & Sciences from 2017 to 2023. Director at Duke University Health System, Inc. and President of the American Society for Clinical Investigation. Program Director at Harvard Mit Health Sciences & Technology from 1999 to 2003. Professor at Duke University from 2007 to 2021. Member of the Scientific Management Review Board at National Institutes of Health from 2014 to 2019. Dean at Harvard Medical School from 2003 to 2007. Dean-Emerita & Vice Chancellor-Emerita at Duke University School of Medicine from 2017 to 2021. Trustee at Massachusetts Institute of Technology. Education includes a doctorate from Massachusetts Institute of Technology, undergraduate and graduate degrees from Yale University, and a doctorate from Harvard Medical School.
Mary Elizabeth Doherty
Mary Elizabeth Doherty currently serves as Independent Non-Executive Director at Novartis AG since 2016, Independent Member-Supervisory Board at Koninklijke Philips NV since 2019, and Independent Member-Supervisory Board at Corbion NV since 2015. Former roles include Independent Non-Executive Director at Nokia Oyj from 2015 to 2016, Finance Director at Unilever Plc, Director at ABI SAB Group Holding Ltd. from 2004 to 2010, Director at Novartis International AG, Senior Independent Director at Dunelm Group Plc from 2017 to 2019, Group Director-International Finance at Tesco Plc from 2001 to 2007, Chief Financial Officer & Director at Reckitt Benckiser Group Plc from 2011 to 2012, Independent Non-Executive Director at Delhaize Le Lion from 2013 to 2016, Chief Financial Officer & Executive Director at Brambles Ltd. from 2007 to 2009, Chief Financial Officer & Executive Director at Reckitt Benckiser Ltd. from 2011 to 2013, Non-Executive Director at United Kingdom Ministry of Justice from 2015 to 2019, Non-Executive Director at Her Majesty's Courts & Tribunals Service from 2015 to 2019, Member-Supervisory Board at Agrolimen SA, Chief Financial Officer at Cognita Ltd. from 2014 to 2015, Chief Financial Officer at Mint Hotel Ltd., and Chief Financial Officer at Cognita Schools Ltd. from 2014 to 2015. Education includes undergraduate degree from The University of Manchester.
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
Ton Büchner
Ton B chner is Chairman-Executive Board & Chief Executive Officer at Akzo Nobel Ltda. since 2013. Chairman at Swiss Prime Site AG and Burckhardt Compression AG since 2020. Independent Non-Executive Director at Novartis AG since 2016. Director at Tonality Holding AG. Member at Ministry of Economic Affairs & Climate. Manager at Bandinnera GmbH and Great Apes Aviation GmbH. Formerly President & Chief Executive Officer at Sulzer AG from 2007 to 2011. Chief Executive Officer at Akzo Nobel NV from 2014 to 2017. Chairman at Burckhardt Compression Holding AG from 2020 to 2025. Director at Novartis International AG. Member-Supervisory Board at Voith GmbH & Co. KGaA from 2014 to 2018. President at Sulzer Pumpen AG from 2003 to 2006. President at Sulzer Turbomachinery Services from 2000 to 2002. Education includes graduate degree from Delft University of Technology and MBA from International Institute for Management Development.
Frans van Houten
Frans van Houten was the founder of Platform for Accelerating the Circular Economy, founded in 2016, serving as Co-Chairman from 2016 to 2022. Mr. van Houten is also the founder of Nl2025..-. Current jobs include Chief Executive Officer at Philips International BV; Chairman at Absci Corp. since 2023; Chairman-Supervisory Board at Stichting Erasmus Trustfonds (SET) since 2014; Chairman at Castor since 2023; Independent Non-Executive Director at Novartis AG since 2017; Non-Executive Director at Vereniging Trustfonds Erasmus Universiteit Rotterdam; Non-Executive Director at World Expo Rotterdam 2025; Director at Ciwit BV since 2023; Director at Synthesis Health, Inc. since 2023; Director at FVH Capital BV; Member at European Round Table of Industrialists since 2010; Member-Supervisory Board at Affidea BV since 2024. Former jobs include Chief Executive Officer at Koninklijke Philips NV from 2011 to 2022; President & Chief Executive Officer at NXP Semiconductors Netherlands BV in 2006; Chief Executive Officer at Philips GmbH; Chief Executive Officer at Signify Holding BV from 2016 to 2017; Chairman & Chief Executive Officer at NXP Semiconductors NV from 2004 to 2009; President & Chief Executive Officer at Airvision LLC from 1992 to 1993; Acting Chief Executive Officer at Philips Lighting Electronics (Shanghai) Co. Ltd.; CEO-Consumer Electronics Businesses Group at Philips Consumer Electronics BV from 1996 to 2004; Co-Chairman at Forum Mondial de L'Economie; Vice Chairman-Supervisory Board at Signify NV from 2016 to 2017; Chairman-Supervisory Board at Erasmus University Trust Fund from 2014 to 2023; VP-International Sales & Operations at PKV Verm gensverwaltung AG from 1993 to 1996; Principal at ING Groep NV from 2009 to 2010. Education includes undergraduate degree in 1982 and graduate degree in 1985 from Erasmus University Rotterdam.
Patrice Bula
Patrice Bula is currently Chairman at Beverage Partners Worldwide (Europe) AG, Froneri International Ltd., Shanghai Totole Flavouring Food Co. Ltd., Froneri Lux Topco SARL, and European Pizza Group Bidco SARL. Vice Chairman at Schindler Holding AG since 2023. Lead Independent Non-Executive Director at Novartis AG since 2022. Director at Life Ventures SA, Tiger LLC, New Tiger International, Inc., and Market Head at Nestl (China) Ltd. Formerly Chief Executive Officer at Cokoladovny AS from 1995 to 1997. Chairman at Blue Bottle Coffee, Inc. from 2017 to 2019. Chairman at Nestl Nespresso SA from 2011 to 2019. Co-Chairman at Cereal Partners Worldwide SA from 2020 to 2021. Director at Bobst Group SA from 2017 to 2019. Marketing Director at Nestl Taiwan Ltd. from 1989 to 1995. Director at Hsu Fu Chi Holdings Ltd. from 2011 to 2019. EVP, Head-Strategic Sales & Marketing at Nestl SA from 2013 to 2021. Education includes graduation from the University of Lausanne.
Bridgette P. Heller
Bridgette P. Heller was the founder of Heller Associates, Inc., founded in 2004, where the title held was Managing Partner from 2004 to 2005. Ms. Heller is the founder of Shirley Proctor Puller Foundation, founded in 2019, holding the title Chief Executive Officer & Director since 2019. Current jobs include Director at Newman's Own Foundation since 2021, Independent Non-Executive Director at Novartis AG since 2020, Independent Director at DexCom, Inc. since 2019, Director at Newman's Own, Inc. since 2020, Director at Market Track LLC since 2021, Independent Director at Aramark since 2021, Director at Integral Ad Science, Inc. since 2021, Trustee at Northwestern University, Trustee at Northwestern University Clinical & Translational Sciences Institute, and Partner at Seedfunders LLC. Former jobs include Chief Executive Officer at Chung's Foods, Inc. from 2003 to 2004; Chairman at Girls, Inc. from 2008 to 2012; Independent Director at Integral Ad Science Holding Corp. from 2021 to 2025; Independent Director at Tech Data Corp. from 2016 to 2020; Director at The ADT Security Corp. from 2012 to 2016; Director at PCA International, Inc. in 2005; President-Baby Global Business Unit at Johnson & Johnson from 2007 to 2010; President-Consumer Care & Executive VP at Merck & Co., Inc. from 2010 to 2015; Executive Vice President & GM-Coffee Division at Mondelez International, Inc. from 1985 to 2002; EVP & GM-North American Coffee Portfolio at Kraft Foods Group, Inc. from 1985 to 2002; President & Executive Vice President at Nutricia Holdings Plc from 2016 to 2019; Executive VP & President-Specialized Nutrition at Danone Nederland BV from 2017 to 2019; President at Merck-Consumer Care from 2010 to 2015; and President-Specialized Nutrition & Executive VP at Danone SA from 2017 to 2019. Education includes undergraduate degree from Northwestern University and an MBAistration from Kellogg School of Management conferred in 1985.
Simon E. Moroney
Simon E. Moroney was the founder of MorphoSys AG, established in 1992, where the title held was Chief Executive Officer from 1992 to 2019. Current jobs include Vice Chairman at Novartis AG since 2022 and Chairman at Biotalys NV since 2021. Former jobs include Director-Supervisory Board at ProtAffin Biotechnologie AG from 2009 to 2011, President at the Government of Germany, Research Associate at the University of Cambridge from 1991 to 1992, Associate-Chemistry Department at Swiss Federal Institute of Technology from 1986 to 1989, Associate at Harvard Medical School from 1984 to 1986, and Assistant Professor at the University of British Columbia from 1989 to 1990. Education history includes a doctorate from the University of Oxford conferred in 1984 and a graduate degree from Waikato University conferred in 1981.
Ana de Pro Gonzalo
Ana de Pro Gonzalo is currently Independent Non-Executive Director at Novartis AG since 2022, Independent Non-Executive Director at Mobico Group Plc since 2019, Member-Supervisory Board at STMicroelectronics NV since 2020, Member-Supervisory Board at Global Steering Group since 2020, and Trustee at Juan Xxiii Foundation since 2020. Former roles include Non-Executive Director at Indra Sistemas SA from 2020 to 2022, Non-Executive Director at Amadeus IT Group SA in 2020, Independent Non-Executive Director at MERLIN Properties SOCIMI SA from 2015 to 2017, General Manager at Sacyr SA from 2002 to 2010, Chief Financial Officer & Deputy General Manager at Metrovacesa SA from 1994 to 2002, and Senior Auditor at Arthur Andersen Y Compania from 1990 to 1994. Education includes undergraduate studies at Universidad Complutense de Madrid.
John D. Young
Mr. John D. Young is an Independent Non-Executive Director at Novartis AG, an Independent Director at Johnson Controls International Plc, a Member at Ministerial Industry Strategy Group, a Member at Life Sciences Council and a Member at National Committee on United States-China Relations, Inc. He is on the Board of Directors at Novartis AG, Johnson Controls International Plc and Johnson Controls, Inc. Mr. Young was previously employed as an Independent Director by Arvinas, Inc., a Group President by Pfizer Essential Health, a Chief Business Officer by Pfizer Inc., a Non-Executive Director by Haleon Plc, a President by Hospira, Inc., and a Chairman & Managing Director by Pfizer Ltd. He also served on the board at Imbria Pharmaceuticals, Inc., Biotechnology Innovation Organization and European Federation of Pharmaceutical Industries & Assns. He received his undergraduate degree from the University of Glasgow and an MBA from Strathclyde Business School.
Charles Swanton
Charles Swanton is the founder of Achilles Therapeutics UK Ltd., founded in 2016. Dr. Swanton is the founder of Achilles Therapeutics Plc, founded in 2020. Dr. Swanton is also the founder of University College London,The Francis Crick Institute Ltd...- Dr. Swanton is Director at American Association for Cancer Research since 2019. Dr. Swanton is Director at Bicycle Therapeutics Plc since 2025. Dr. Swanton is Director at Novartis AG since 2026. Former jobs include Co-Director-Lung Cancer Centre of Excellence at Cancer Research UK and a position at UCL Medical School. Education includes undergraduate degree from UCL Medical School.